2015, Number 2
<< Back Next >>
Rev Cub Oftal 2015; 28 (2)
Results of the treatment of thyroid orbinopathy and factors affecting the therapeutic response
Cáceres TM, Márquez FM, Ballate NE, Cáceres TO, Jiménez PR, Gutiérrez RÁ
Language: Spanish
References: 52
Page: 177-189
PDF size: 147.55 Kb.
ABSTRACT
Objective: to evaluate the results of the treatment of thyroid orbinopathy and to
determine the factors affecting them.
Methods: observational study of a cohort of 82 patients with thyroid orbinopathy
during the 1997-2009 period.
Results: corticosteroid-bases therapy began nineteen months after the onset of
disease and was unsatisfactory in most of cases with active thyroid orbitopathy, so it
was necessary to perform several surgeries to preserve the vision. The influential
factors on the therapeutic response were smoking and thyroid orbinopathy activity
(OR= 30,479 and OR= 14,557, respectively). Good results were attained with
botilinum toxin A and strabismus correction surgery and retraction.
Conclusions: early diagnosis and treatment is the best therapy for patients with
thyroid orbinopathy. Smoking and thyroid orbinopathy negatively affect the
therapeutic response. Botulinum toxin A and surgery are effective options in the
strabismus correction and palpebral retractions of thyroid orbinopathy.
REFERENCES
Pérez Moreiras JV, Coloma Bockos JE, Prada Sánchez MC. Orbitopatía tiroidea. Fisiopatogenia, diagnóstico y tratamiento. Arch Soc Esp Oftalmol. 2003;78(8):407-31.
Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease. Curr Opin Ophthalmol. 2008;19(6):499-506.
Tucker S, Tucker N, Linberg JV. Diseases of the orbit. En: Tasman E, Jaeger E (ed). Duane’s Ophthalmology [CD-ROM]. Lippincott Williams and Wilking; 2008.
Ing E, Roy H. Thyroid-Associated Orbitopathy. Medscape. 2011 [citado 29 de enero de 2014]. Disponible en: http://emedicine.medscape.com/article/1218444-overview
Eckstein A, Losch C, Glowacka D, Schott M, Mann K, Esser J, et al. Euthyroid and primary hypothyroid patients develop milder and significantly more asymmetrical Graves Ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052-6.
Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol. 2010;55(3):215-26.
Kumar S, Nadeem S, Stan M, Coenen M, Bahn R. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol. 2011;46(3):155-63.
Wiersinga W, Perros P, Kahaly G, Mourits M, Baldeschi L, Boboridis K. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387-89.
Bartalena L. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clin Endocrinol. 2010;73(2):149-52.
Rootman J, Dolman PJ. Thyroid Orbitopathy. In: Rootman J. Diseases of the Orbit. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 169-212.
Cáceres M, Cáceres O, La OY. Orbitopatía tiroidea. Alternativas terapéuticas. En: Colectivo de Autores. Manual de Prácticas Médicas del Hospital "Hermanos Ameijeiras". La Habana: ECIMED; 2012. p. 825-8.
Río M, Capote A, Hernández J, Eguía F, Padilla C. Oftalmología. Criterios y tendencias actuales. La Habana: Editorial Ciencias Médicas; 2009.
Achiong F, Morales JM, Acebo F, Bermúdez CL, Garrote I. Prevalencia y riesgo atribuible al tabaquismo. Rev Cubana Hig Epidemiol. 2006 [citado 28 de enero de 2012];44(1):[aprox 19 p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_pdf&pid=S1561- 30032006000100001&lng=es&nrm=iso&tlng=es
Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B. The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol. 2009;161(3):483-87.
Zegada JA, López DA. Uso de triamcinolona en orbitopatía tiroidea. Gac Med Bol. 2009;32(2):39-43.
Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(8):2708-16.
Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe corticosteroid-resistant thyroidassociated ophthalmopathy. Ophthalmology. 2010;117(1):133-39.
Kalmann R, Mourits MP, van der Pol JP, Koornneef L. Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy. Br. J Ophthalmol. 1997;81(1):41-5.
Montes de Oca F, Martínez J, Cubero D, Cáceres M, Montes de Oca M, García A. Cirugía en los tumores orbitarios. Experiencia de 10 años. Rev Chil Neurocir. 2011;36:27-32.
Cáceres M, Márquez M, Caballero Y, Córdova G. Descompresión orbitaria en la orbitopatía tiroidea. Rev Cubana Oftalmol. 2008 [citado 28 de enero de 2012];21(1):[aprox 7 p.] Disponible en: http://www.bvs.sld.cu/revistas/oft/vol21_1_08/oft01108.htm
Cáceres M, Arboláez O, Cáceres O. Descompresión orbitaria por endoscopia nasal en la orbitopatía tiroidea. Presentación de un caso. Vision Pan-America. 2011;10:84-6.
Maciques Rodríguez JE, Cáceres Toledo M. Orbitopatía tiroidea. Rev Cubana Endocrinol. 2012;23(3):225-33.
Pletcher SD, Sindwani R, Metson R. Endoscopic orbital and optic nerve decompression. Otolaryngol Clin North Am. 2006;39(5):943-58.
Chu EA, Miller NR, Lane AP. Selective endoscopic decompression of the orbital apex for dysthyroid optic neuropathy. Laryngoscope. 2009;119(6):1236-40.
Yan J, Zhang H. The surgical management of strabismus with large angle in patients with Graves´ophthalmopathy. International Ophthalmology. 2008;28(2):75-82.
Seo Y, Kyung SE, Chang M. Results of Surgical Treatment for Paralytic Strabismus. J Korean Ophthalmol Soc. 2009;50(9):1377-85.
Nassar MM, Dickinson AJ, Neoh C, Powell C, Buck D, Galal E, et al. Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy. J AAPOS. 2009;13(3):236-40.
Cáceres M, Márquez M, Cáceres O, Fresneda J. Aplicaciones del Gore-tex en Oftalmología. Rev Cubana Oftalmol. 2014;27(1):62-9.
Langmann A, Lindner S, Wackernagel W, Koch M, Horantner R. Polytetrafluoroethylene (Goretex) for muscle elongation in the surgical treatment of strabismus with restricted motility. Acta Ophthalmol Scand. 2006;84(2):250-3.
Kassem R, Gawdat G, Zedan R. Severe fibrosis of extraocular muscles after the use of lyophilized amniotic membrane in strabismus surgery. JAAPOS. 2010;14(6):548-49.
Kikkawa O. Histopathologic analysis of palpebral conjunctiva in Thyroid Related Orbitopathy. Trans Am Ophthalmol Soc. 2010;108:46-61.
Costa P, Saraiva FP, Pereira IC, Monteiro ML, Matayoshi S. Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye. 2009;23(4):767-73.
Shih MJ, Liao SL, Lu HY. A single transcutaneous injection with Botox for dysthyroid lid retraction. Eye. 2004;18(5):466-9.
Biglan AW. Control of eyelid retraction associated with Graves' disease with Botulinum-A toxin. Ophthalmic Surg. 1994;25(3):186-8.
Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjuntival botulinum toxin injection. Ophthalmology. 2002;109(6):1183-7.
Träisk F, Tallstedt L. Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction. A pilot study. Acta Ophthalmol Scand. 2001;79(6):585-8.
Dintelmann T, Sold J, Grehn F. Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease. Ophthalmologe. 2005;102(3):247-50.
Rowe F, Noonan C. Toxina botulínica para el tratamiento del estrabismo. Revista Cochrane traducida. En: Biblioteca Cochrane Plus; 2009 [citado 28 de enero de 2012]. Disponible en: http://www.update-sofwere.com
Rowe F, Noonan C, Batra R. Dose effect of botulinum toxin A in heterotropia and heterophoria. Strabismus. 2010;18(1):3-7.
Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924-97.
Scott AB, Miller JM, Shieh KR. Treating strabismus by injecting the agonist muscle with bupivacaine ad the antagonist with botulinum toxin. Trans Am Ophthalmol Soc. 2009;107:104-9.
Moguel-Ancheita S, Dixon-Olvera S, Martínez-Oropeza S, Orozco-Gómez LP. Utilidad de la toxina botulínica en el tratamiento del estrabismo en enfermedades sistémicas. Arch Soc Esp Oftalmol. 2003;78(1):9-14.
Albanese A. Terminology for preparations of botulinum neurotoxins. JAMA. 2011;305(1):89-90.
Kikkawa DO, Cruz RC Jr, Christian WK, Rikkers S, Weinreb R, Levi L, et al. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: Effect on intraocular pressure. Am J Ophthalmol. 2003;135(4):427-31.
Kumar S, Mohiuddin Araf M. Therapeutic application of botulinum toxin in clinical practice. Op Gen Int Med J. 2009;3:14-9.
Kaynak-Hekimhan P. Non cosmetic periocular therapeutic applications of botulinum toxin. Middle East Afr J Ophthalmol. 2010;17(2):113-20.
Hornik A, Gruener G, Jay W. Adverse reactions from botulinum toxin administration. Neuro-Ophthalmology. 2010;34(1):6-13.
Rowe F, Noonan C. Complications of botulinum toxin A and their adverse effects. Strabismus. 2009;17(4):139-42.
De Alba Campomanes AG, Binenbaum G, Campomanes Eguiarte G. Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia. J AAPOS. 2010;14(2):111-6.
Thornton J, Nelly SP, Harrison RA, Edwars R. Cigarette smoking and thyroid eye disease a systematic review. Eye. 2007;21(9):135-45.
Lois N, Abdelkader E, Reglitz K, Garden C, Ayres JG. Environmental tobacco smoke exposure and eye disease. Br J Ophthalmolol. 2008;92(10):1304-10.
Lee H, Roh HS, Yoon JS, Lee SY. Assessment of quality of life and depression in Korean patients with Graves' Ophthalmopathy. Korean J Ophthalmol. 2010;24(2):65-72.